Skip to main content
. 2013 Mar;9(2):161–193. doi: 10.2174/1573399811309020007

Fig. (7).

Fig. (7)

ExBID treatment reduced HbA1c and body weight in patients with T2DM in the three pivotal phase 3 clinical trials on differing oral antidiabetes drug backgrounds. At Week 30, significant HbA1c and weight reductions were observed in all ExBID groups compared with placebo (p<0.05). LS mean±SEM. (Adapted from references [92,95,105]).